Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes

Nagaraja M. Phani, Manik Vohra, Ananth Kakar, Prabha Adhikari, Shivashankara K. Nagri, Sydney C. D'Souza, Shashikiran Umakanth, Kapaettu Satyamoorthy, Padmalatha S. Rai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.

Original languageEnglish
Pages (from-to)905-911
Number of pages7
JournalPharmacogenomics
Volume19
Issue number11
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Metformin
Type 2 Diabetes Mellitus
Pharmacokinetics
Genes
Therapeutics
Hypoglycemic Agents
Single Nucleotide Polymorphism
Genotype
Prospective Studies
Glucose
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Phani, Nagaraja M. ; Vohra, Manik ; Kakar, Ananth ; Adhikari, Prabha ; Nagri, Shivashankara K. ; D'Souza, Sydney C. ; Umakanth, Shashikiran ; Satyamoorthy, Kapaettu ; Rai, Padmalatha S. / Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes. In: Pharmacogenomics. 2018 ; Vol. 19, No. 11. pp. 905-911.
@article{8dfe705659a44d4188227d3ee35ef051,
title = "Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes",
abstract = "Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.",
author = "Phani, {Nagaraja M.} and Manik Vohra and Ananth Kakar and Prabha Adhikari and Nagri, {Shivashankara K.} and D'Souza, {Sydney C.} and Shashikiran Umakanth and Kapaettu Satyamoorthy and Rai, {Padmalatha S.}",
year = "2018",
month = "1",
day = "1",
doi = "10.2217/pgs-2018-0041",
language = "English",
volume = "19",
pages = "905--911",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "11",

}

Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes. / Phani, Nagaraja M.; Vohra, Manik; Kakar, Ananth; Adhikari, Prabha; Nagri, Shivashankara K.; D'Souza, Sydney C.; Umakanth, Shashikiran; Satyamoorthy, Kapaettu; Rai, Padmalatha S.

In: Pharmacogenomics, Vol. 19, No. 11, 01.01.2018, p. 905-911.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes

AU - Phani, Nagaraja M.

AU - Vohra, Manik

AU - Kakar, Ananth

AU - Adhikari, Prabha

AU - Nagri, Shivashankara K.

AU - D'Souza, Sydney C.

AU - Umakanth, Shashikiran

AU - Satyamoorthy, Kapaettu

AU - Rai, Padmalatha S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.

AB - Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.

UR - http://www.scopus.com/inward/record.url?scp=85049916591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049916591&partnerID=8YFLogxK

U2 - 10.2217/pgs-2018-0041

DO - 10.2217/pgs-2018-0041

M3 - Article

VL - 19

SP - 905

EP - 911

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 11

ER -